Cargando…

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients

BACKGROUND: Cardiac surgery has been shown to result in a significant decrease of the antioxidant selenium, which is associated with the development of multiorgan dysfunction and increased mortality. Thus, a large-scale study is needed to investigate the effect of perioperative selenium supplementat...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoppe, Christian, McDonald, Bernard, Rex, Steffen, Manzanares, William, Whitlock, Richard, Fremes, Stephen, Fowler, Robert, Lamarche, Yoan, Meybohm, Patrick, Haberthür, Christoph, Rossaint, Rolf, Goetzenich, Andreas, Elke, Gunnar, Day, Andrew, Heyland, Daren K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247649/
https://www.ncbi.nlm.nih.gov/pubmed/25169040
http://dx.doi.org/10.1186/1745-6215-15-339
_version_ 1782346673834426368
author Stoppe, Christian
McDonald, Bernard
Rex, Steffen
Manzanares, William
Whitlock, Richard
Fremes, Stephen
Fowler, Robert
Lamarche, Yoan
Meybohm, Patrick
Haberthür, Christoph
Rossaint, Rolf
Goetzenich, Andreas
Elke, Gunnar
Day, Andrew
Heyland, Daren K
author_facet Stoppe, Christian
McDonald, Bernard
Rex, Steffen
Manzanares, William
Whitlock, Richard
Fremes, Stephen
Fowler, Robert
Lamarche, Yoan
Meybohm, Patrick
Haberthür, Christoph
Rossaint, Rolf
Goetzenich, Andreas
Elke, Gunnar
Day, Andrew
Heyland, Daren K
author_sort Stoppe, Christian
collection PubMed
description BACKGROUND: Cardiac surgery has been shown to result in a significant decrease of the antioxidant selenium, which is associated with the development of multiorgan dysfunction and increased mortality. Thus, a large-scale study is needed to investigate the effect of perioperative selenium supplementation on the occurrence of postoperative organ dysfunction. METHODS/DESIGN: We plan a prospective, randomized double-blind, multicenter controlled trial, which will be conducted in North and South America and in Europe. In this trial we will include 1,400 high-risk patients, who are most likely to benefit from selenium supplementation. This includes patients scheduled for non-emergent combined and/or complex procedures, or with a predicted operative mortality of ≥5% according to the EuroSCORE II. Eligible patients will be randomly assigned to either the treatment group (bolus infusion of 2,000 μg sodium selenite immediately prior to surgery, followed by an additional dosage of 2,000 μg at ICU admission, and a further daily supplementation of 1,000 μg up to 10 days or ICU discharge) or to the control group (placebo administration at the same time points). The primary endpoint of this study is a composite of 'persistent organ dysfunction’ (POD) and/or death within 30 days from surgery (POD + death). POD is defined as any need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or new intermittent hemodialysis) at any time within 30 days from surgery. DISCUSSION: The SUSTAIN-CSX™ study is a multicenter trial to investigate the effect of a perioperative high dosage sodium selenite supplementation in high-risk cardiac surgical patients. TRIAL REGISTRATION: This trial was registered at Clinicaltrials.gov (identifier: NCT02002247) on 28 November 2013. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1745-6215-15-339) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4247649
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42476492014-11-30 SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients Stoppe, Christian McDonald, Bernard Rex, Steffen Manzanares, William Whitlock, Richard Fremes, Stephen Fowler, Robert Lamarche, Yoan Meybohm, Patrick Haberthür, Christoph Rossaint, Rolf Goetzenich, Andreas Elke, Gunnar Day, Andrew Heyland, Daren K Trials Study Protocol BACKGROUND: Cardiac surgery has been shown to result in a significant decrease of the antioxidant selenium, which is associated with the development of multiorgan dysfunction and increased mortality. Thus, a large-scale study is needed to investigate the effect of perioperative selenium supplementation on the occurrence of postoperative organ dysfunction. METHODS/DESIGN: We plan a prospective, randomized double-blind, multicenter controlled trial, which will be conducted in North and South America and in Europe. In this trial we will include 1,400 high-risk patients, who are most likely to benefit from selenium supplementation. This includes patients scheduled for non-emergent combined and/or complex procedures, or with a predicted operative mortality of ≥5% according to the EuroSCORE II. Eligible patients will be randomly assigned to either the treatment group (bolus infusion of 2,000 μg sodium selenite immediately prior to surgery, followed by an additional dosage of 2,000 μg at ICU admission, and a further daily supplementation of 1,000 μg up to 10 days or ICU discharge) or to the control group (placebo administration at the same time points). The primary endpoint of this study is a composite of 'persistent organ dysfunction’ (POD) and/or death within 30 days from surgery (POD + death). POD is defined as any need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or new intermittent hemodialysis) at any time within 30 days from surgery. DISCUSSION: The SUSTAIN-CSX™ study is a multicenter trial to investigate the effect of a perioperative high dosage sodium selenite supplementation in high-risk cardiac surgical patients. TRIAL REGISTRATION: This trial was registered at Clinicaltrials.gov (identifier: NCT02002247) on 28 November 2013. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1745-6215-15-339) contains supplementary material, which is available to authorized users. BioMed Central 2014-08-28 /pmc/articles/PMC4247649/ /pubmed/25169040 http://dx.doi.org/10.1186/1745-6215-15-339 Text en © Stoppe et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Stoppe, Christian
McDonald, Bernard
Rex, Steffen
Manzanares, William
Whitlock, Richard
Fremes, Stephen
Fowler, Robert
Lamarche, Yoan
Meybohm, Patrick
Haberthür, Christoph
Rossaint, Rolf
Goetzenich, Andreas
Elke, Gunnar
Day, Andrew
Heyland, Daren K
SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
title SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
title_full SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
title_fullStr SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
title_full_unstemmed SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
title_short SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
title_sort sodium selenite adminstration in cardiac surgery (sustain csx-trial): study design of an international multicenter randomized double-blinded controlled trial of high dose sodium-selenite administration in high-risk cardiac surgical patients
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247649/
https://www.ncbi.nlm.nih.gov/pubmed/25169040
http://dx.doi.org/10.1186/1745-6215-15-339
work_keys_str_mv AT stoppechristian sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT mcdonaldbernard sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT rexsteffen sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT manzanareswilliam sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT whitlockrichard sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT fremesstephen sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT fowlerrobert sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT lamarcheyoan sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT meybohmpatrick sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT haberthurchristoph sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT rossaintrolf sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT goetzenichandreas sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT elkegunnar sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT dayandrew sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients
AT heylanddarenk sodiumseleniteadminstrationincardiacsurgerysustaincsxtrialstudydesignofaninternationalmulticenterrandomizeddoubleblindedcontrolledtrialofhighdosesodiumseleniteadministrationinhighriskcardiacsurgicalpatients